In the series, “The HPV Vaccine: A Double-Edged Sword?” we will provide documented evidence of death and severe injuries linked with Gardasil, analyze the root cause of its harm, and offer solutions.
Let’s shift the lens to the beautiful Pyrenees in Europe where sheep were cherished for their wool, nourishment, and companionship. However, a mysterious sheep illness occurred around a decade ago.
Mysterious Post-Vaccine Sheep Illness
In August 2006, an outbreak of bluetongue disease quickly spread to European countries causing a state of emergency.
Bluetongue disease, caused by bluetongue virus (BTV), affects ruminants, mainly sheep, with symptoms of fever, hemorrhages, depression, edemas, and generalized cyanosis, easily observed on the tongue, which explains the disease name.
The totally unexpected outbreak caused by a newly emerged BTV serotype led to a massive compulsory European vaccination campaign implemented between 2007 and 2010. The administered vaccine contained a new ingredient not used in previous BTV vaccines—aluminum (Al)—with 2.08 milligrams per milliliter as the adjuvant, in addition to inactivated BTV.
The campaign seemed to effectively halt viral spreading, however, during the same vaccination period, a series of previously unreported severe diseases emerged in France, Germany, Switzerland, the UK, and Spain, featuring weakness and various neurological symptoms. Veterinarians were stumped, as no known disease explained the tragedy.
Sheep Study Identifies the Problem
Dr. Lluis Lujan, an associate professor of veterinary pathology at the University of Zaragoza in Spain, conducted a sheep study to determine the cause of the unusual diseases.
A total of 21 sheep were assigned into three groups (red, yellow, and green) with seven in each group as follows:
- The red group received commercial sheep vaccines containing aluminum hydroxide.
- The yellow group received the equivalent dose of aluminum dissolved in water (Alhydrogel®, an aluminum-based adjuvant).
- The green group was administered a neutral saltwater solution.
Surprisingly, both the animals from the red and yellow groups became significantly more aggressive and showed more stereotypes and higher stress.
The detected level of aluminum found in the lymph nodes in the lumbar spinal cord was much higher in both the aluminum-only (yellow) and the vaccine group (red) compared with the control group, indicating that aluminum created an extra burden needing to be processed by the sheep.
This explained the phenomenon that the sheep illness occurred only after the aluminum was added to the vaccine as an adjuvant. “So for me, yes—the reason why the animals get sick after vaccination is how the body deals with aluminum,” Dr. Lujan stated in a documentary film “Under the Skin,” available on Epoch TV.
The idea is not only about sheep. We are looking for something that could be happening in humans.
‘Placebo’ Trial Participant Had 40+ Symptoms
The Phase 3 clinical trial for Gardasil (FUTURE II study) began in 2002. A particularly large number of participants were recruited in Denmark.
Gardasil clinical trial participant, Sesilje Petersen, developed severe fatigue and a total of 40 symptoms after the second and third shots.
“It was the biggest problem because I was a student at the university and it was very difficult for me to attend the classes as I fell asleep almost daily,” Sesilje said. “I wrote a list with all my symptoms—there were more than 40 symptoms, and some of them had been severe. I had a tumor on my pituitary gland.”
“I received a letter and was invited to this study and it sounded very interesting. So I decided to participate,” recalled Sesilje.
Sesilje kept the information brochure that the participants received at the beginning of the study. It said that the vaccination had already been carefully tested for safety and did not have any serious side effects.
The information about the placebo turned out to be a lie. “It says here that the placebo was saline—the Danish word for saltwater,” she said.
Aluminum: A Toxin in Vaccines for 90 Years
Sesilje’s “saline” placebo contained something highly unusual—aluminum (Al), an adjuvant commonly used in modern vaccines.
She was obviously misinformed about the study design and was unaware of what she was receiving. Prior to participating in the Gardasil study, Sesilje knew that she could not tolerate deodorants containing aluminum.
“We were not informed about the use of aluminum. The word aluminum was not given to us either in the procedure or in their phone consent form.” Sesilje said.
In fact, a study by Doshi et al. found that participants in the Gardasil trials were not adequately informed that the placebo was amorphous aluminum hydroxyphosphate sulfate (AAHS). The trial participants were told they could receive a “placebo” without being informed of noninert ingredients (AAHS). This raises serious ethical concerns about the trial conduct.
Aluminum was first used in human vaccines in 1932 and was the only adjuvant used in licensed vaccines for approximately 70 years. This controversial compound is still used as an adjuvant in vaccines, however, what is its actual role?
Aluminum is the third most abundant metal in the earth’s crust and is widely present in the environment—in plants, soil, water, air, food, and pharmaceuticals. It is present in an ionic form as Al3+.
The absorption of aluminum depends on several factors such as the pH level and the presence of organic acids (citrate, lactate). It is absorbed in a proportion of only 0.1 to 0.3 percent by the gastrointestinal tract in the upper intestine.
However, when aluminum is injected into our muscles in the formulation of a vaccine, it is nearly 100 percent absorbed. It then travels and crosses the blood-brain barrier and accumulates in our brain and other organs.
Aluminum is a well-known cell killer. It creates harmful molecules called reactive oxygen species, misleads the immune system to become overreactive to our body components, damages the energy supply chain, and is toxic to our DNA.
Aluminum is especially harmful to our brain and nerves, as it plays multiple roles in the clumping of harmful substances (β-amyloid, tau protein) in the brain, leads to the death of brain-protective cells called astrocytes, and disrupts the “protective wall” around the brain resulting in more vulnerability to harmful substances.
Christopher Exley, an English professor of bioinorganic chemistry, is one of the most knowledgeable and widely-cited aluminum researchers in the world, with over 200 peer-reviewed scientific papers published on aluminum and over 12,000 citations.
Renal failure patients dialyzed have developed encephalitis linked to excessive brain buildup of aluminum. Those who passed away had a tenfold higher level of aluminum in gray matter, leading to fatal brain diseases in 30 to 50 percent of cases. Their brain symptoms were correlated with their blood aluminum levels, including issues of speech, coordination, cognition, and fatal seizures.
Dietary absorbed ionic aluminum can leave our body through the kidneys, however, most antigen-aluminum mixtures in vaccines are too large for the kidneys to expel out of our body. Accordingly, vaccine aluminum exposure poses a much higher safety risk than dietary aluminum.
According to the U.S. Food and Drug Administration (FDA), a placebo is defined as “an inactive pill, liquid, or powder that has no treatment value.” The well-established toxic properties of aluminum therefore suggest that aluminum cannot constitute a valid placebo.
Toxicity Makes Aluminum an Adjuvant
Almost all modern diseases have their origin in a disturbed immune system. No other drug intervenes in the immune system as intensively as vaccines. The role of vaccine components in human immunity is discussed without taboos in the scientific community.
The gold standard to evaluate the effectiveness of a vaccine is based on the antibody level generated. In the beginning, people were not satisfied with a pure inactivated virus to provoke an immune response and wanted to find a substance to help boost immunity and generate a more robust response with longer-sustained antibodies—that is the adjuvant.
Aluminum was found to be a strong adjuvant.
According to Mr. Exley, “The known toxicity of aluminum is almost certainly a contributor to the success of aluminum-based salts as adjuvants.”
A 2016 Nature study provided insight into the cellular toxicity induced by aluminum used as an adjuvant in clinically-approved human vaccinations.
When we inject a vaccine with aluminum into the muscle, we can only imagine what physical and chemical reactions will be triggered. At the very beginning, there may be little response at the injection site. The only reaction may be due to the damage caused by the needle.
“When the vaccine is injected deeply into the muscle tissue, aluminum ions begin to dissolve and start attacking the surrounding cells,” Mr. Exley stated in the documentary “Under the Skin.”
“So depending upon that rate of dissolution, you will get the degree of cytotoxicity—cell toxicity,” he said.
The aluminum ions kill our normal healthy cells and as those cells die, they release chemical messengers, which call for help from the other immune cells.
Immune cells react immediately and start to attack anything suspicious at the vaccination site. A fierce battle takes place.
It is only in the course of this inflammation triggered by aluminum that the silent antigens are now also taken seriously and are transported away by specialized immune cells. Those silent viral proteins are also identified by immune cells as enemies and specific antibodies are produced to bind them.
As a result, scientists are using aluminum’s toxic effects that can trigger inflammation to begin a battle against an inactive antigen. The toxicity level of aluminum is an alternative term used to describe its ability to produce antibodies in a vaccine.
Manipulated and Unethical Study
Sesilje’s experience of receiving a placebo containing aluminum instead of saline illustrates how a clinical trial can be designed to manipulate the study results while deceiving study participants. The published New England Journal of Medicine (NEJM) paper Gardasil FUTURE II clinical trial data clearly states that subjects were receiving either quadrivalent Gardasil or “a visually indistinguishable aluminum-containing placebo.”
Why did the Gardasil clinical trials choose to use aluminum as a comparator instead of saline?
Based on standard pharma clinical research, a normal vaccine study design should use a real placebo (e.g., saline) as a comparative group. Instead, the placebo group in the Gardasil FUTURE II study used a pseudo placebo, which means that it is not a true placebo, but contains a pharmacologically active compound—in this case, it’s aluminum. This is not normal.
“If some of these girls develop the same rare harms, then you can’t see the difference. It’s magic. You mask it, it’s magic. This should not be allowed,” said Dr. Peter Gøtzsche in the documentary “Under the Skin.”
Dr. Gøtzsche is a Danish physician, professor of clinical research design and analysis, and the former leader of the Nordic Cochrane Center in Copenhagen, Denmark. He is also a co-founder of the Cochrane Collaboration and has published more than 70 papers in the so-called “Big Five” journals: New England Journal of Medicine, The Lancet, Annals of Internal Medicine, British Medical Journal, and Journal of the American Medical Association. His scientific works have been cited over 30,000 times.
In his paper, “Aluminium-Based Adjuvants Should Not Be Used as Placebos in Clinical Trials,” Mr. Exley stated:
“It is necessary to make a very strong scientific case for using a placebo which is itself known to result in side effects, and I have not found any scientific vindication for such in the recent human vaccination literature. While severe adverse effects following vaccination are rare, it should not be acceptable to ignore or nullify those effects, which are due to the aluminum-based adjuvant either acting alone or in combination with the antigen. To do so could place susceptible individuals at risk.”
By using such a deliberate study design, 2.3 percent of the participants in the Gardasil group developed systemic autoimmune disorders that occurred at exactly the same rate as those in the aluminum “placebo” group. However, the 2.3 percent of girls and women harmed in the aluminum-treated group is considered unethical and should never have happened.
The true purpose of dosing such an unethical study design appears to have been to hide Gardasil’s ability to harm by keeping it below the manipulated dark background.
In Parts 1 and 2 of this series, we presented undeniable deaths and severe injuries after HPV vaccination. These harms were often ignored by doctors and scientists, as they were tactically hidden by careful study design to show that the placebo group had the same rate of adverse effects as the vaccine group. This made it appear as if the harms were due to natural causes in the unvaccinated population.
Many have been cheated by this blatant lie.
Invalid Risk-Benefit Assessment
Dr. Enrica Alteri, the former head of risk management and epidemiology at Merck-Serono in Geneva, was appointed as the head of EMA’s Safety and Efficacy of Medicines on July 2, 2012. Her move from private industry to a public sector position is an example of “revolving door” regulatory politics, raising serious concerns about the possibility of pro-industry biases in national health care decision-making.
Gardasil was developed by Merck.
Dr. Alteri announced the complete acquittal of the HPV vaccination, according to her statement, as reported in the documentary “Under the Skin.”
“We can confirm today the safety of the HPV vaccine. There is no reason to change the way the vaccines are used or amend the current product information,” she said.
So the magic worked—not only did the health authorities conclude that Gardasil is completely safe, but the scientific community has also been cheated by the Gardasil trial design.
Why couldn’t they see the truth with the placebo group design? Were they easily fooled or complicit?
To reveal more of the truth behind the studies, three scientists, including two from the Nordic Cochrane Centre in Copenhagen, Demark—Lars Jørgensen and Tom Jefferson, along with Dr. Peter Gøtzsche, a previous co-founder of Cochrane, conducted a rigorous, independent systematic review of 24 HPV vaccine clinical study reports. The review included 95,670 participants (83 percent female) aged 8 to 72 who were followed for an average of 49 months.
One of the most shocking findings, based on the source data, was that 96.3 percent of participants in the control groups of those studies received aluminum-based adjuvants. This distorted (to an unknown extent) an accurate assessment of the harms caused by the HPV vaccine.
The authors judged “all 24 studies to be at high risk of bias” due to their study design. The included trials were primarily designed to assess benefits and were not properly designed to assess harms by using aluminum, a toxin, as the comparator, making it impossible to determine the actual harms caused by the HPV vaccines.
The current risk-benefit assessment for Gardasil is invalid, as they did not compare the Gardasil vaccine with something benign (saline), but instead compared it with a major component of the vaccine (aluminum).
A 2018 doctoral thesis by Dr. Lars Jørgensen concluded that it is impossible to conduct a risk-benefit analysis of the Gardasil vaccine, as most of the Gardasil studies have used AAHS as a comparator, which is known to cause harm.
The aluminum in Gardasil vaccines is a serious issue. Aluminum in any vaccine can have dire consequences, especially when administered to infants, as we see in one baby’s death.
Infant Dies After Vaccination
On Oct. 28, 2022, a 62-day-old baby, Sawyer, died 34 hours after receiving his scheduled childhood vaccines. While living in Maine, his parents had been seeking an explanation for the cause of their son’s death for nearly a year. Finally, a toxicology report indicated that Sawyer’s blood contained 95 μg/L of aluminum, a level considered toxic for adults. Signs of neurotoxicity are observed with blood aluminum levels of more than 60 μg/L.
In fact, by the year 2005, infants started to receive 4925 μg of aluminum in their first 18 months of vaccinations, not counting the other sources of exposure such as food, skin, and milk.
Aluminum in Vaccines ‘Akin to a Lottery’
A lot of vaccines on the childhood schedule in the United States contain aluminum adjuvants. Furthermore, the content of aluminum in vaccines is not under strict control by regulatory authorities.
A study published in the Journal of Trace Elements in Medicine and Biology found the amount of aluminum an infant receives in a vaccine is far from being predictable or controlled and seems to be “akin to a lottery.”
In 10 of 13 vaccines, the measured quantity of aluminum failed to match up to the amount of aluminum reported by manufacturers in patient information leaflets, according to the study.
Analysis across vaccines and vaccine lots revealed the following:
- Six of the vaccines, including Pfizer’s Prevnar 13, contained a statistically significant greater quantity of aluminum than the manufacturer stated.
- Four of the vaccines contained significantly less aluminum than the manufacturer stated.
- For each single vaccine brand, the range of aluminum content “varied considerably.”
Neither the EMA nor the FDA could confirm they independently or routinely measure the aluminum content of infant vaccines, instead indicating that they rely upon manufacturers’ (flawed) data.
Sources of Aluminum Exposure
Those who argue that the limited aluminum in childhood vaccines can’t lead to health issues often overlook the accumulated aluminum exposure (the full “body burden”) from various sources in our environment.
Aluminum is found widely in our environment, not only as a vaccine adjuvant, but also in water, processed foods, food packages, cookware, cosmetics, medications, and medical ware.
Food and water:
- Infant formula or breast milk from mothers who have been exposed to aluminum.
- Cookware, foil-like packaging, and aluminum cans.
- Aluminum salts in many prepared foods.
- Aluminum sulfate used for making bread white.
- Food contamination through food processing using aluminum machinery.
- Fish exposed to aluminum contaminants.
- Contamination of tea, coffee, tobacco, marijuana, soy, and other edible plant products from aluminum in acidic soil resulting from poor farming practices. (Acidic soil is better able to take up aluminum, and glyphosate is a strong aluminum binder at low pH levels.)
- Aluminum salts are commonly used as coagulants in the water treatment process to remove impurities and particles.
- Medications such as antacids, phosphate binders used for kidney dialysis, buffers present in many painkillers, and intravenous preparations for babies and hospitalized adults.
- Transfused fluid such as blood warming devices.
- Prosthetic devices for hip replacements and dental products.
Cosmetics and deodorants may also contain aluminum.
Diseases Linked to Aluminum in Vaccines
While old vaccines contain antigens without adjuvants, a newer generation of vaccines typically requires the addition of adjuvants, a substance as aforementioned that fires the immune system to produce antibodies to the antigen.
Aluminum adjuvants alone have been associated with a number of adverse effects. The local signs of inflammation (injection site pain and tenderness, and contact dermatitis) explain aluminum’s toxicity and ability to destroy cells.
In addition, the toxic effects of aluminum salts to induce cell death and inflammation could also explain why some subjects develop persistent lumps and granulomas at the injection site.
Aluminum adjuvants in vaccines may produce an unbalanced immune response, leaning too much toward a biased response to Th2, a cell that potentially causes more allergies and severe reactions. It’s especially concerning in children who are already prone to allergies. In some cases, aluminum-adjuvanted vaccines have been linked to lung problems when the person later encounters the virus the vaccine was meant to protect against. This may help explain why more children and adults are allergic to a greater number of substances nowadays.
Furthermore, more safety concerns about the long-term effects of aluminum hydroxide used in vaccines have been raised.
Aluminum salts can also cause severe adverse events such as macrophagic myofasciitis (MMF), a condition with unknown origin, found in patients experiencing muscle pain and fatigue. In a study published in the journal Brain, all patients with MMF had received vaccines containing aluminum hydroxide, such as those for hepatitis B, hepatitis A, or tetanus, before developing symptoms. The study suggests that MMF is linked to the injection of aluminum hydroxide-containing vaccines and shows persistent inflammation at the injection site.
An important side effect of aluminum is “autoimmune/inflammatory syndrome induced by adjuvants.” This happens because aluminum can stick firmly to cells and proteins, which can modify our protein’s three-dimensional shape, making them look different. T-cells may mistake these altered proteins as “nonself,” leading to an autoimmune response.
Furthermore, the HPV virus protein has overlapping structures with human proteins, which is called cross-reactivity. A 2019 study by Italian and Israeli scientists examined the proteins used in the HPV vaccine and concluded that they overlap with some human proteins.
This is particularly detrimental because if a vaccinated person develops antibodies to the Gardasil vaccine’s proteins, it could potentially train their immune system to attack some of their own cells, leading to a range of autoimmune diseases.
As a result, a person vaccinated with Gardasil has an immune system response that generates not only antibodies to the HPV antigen but also attacks components of their nerves and mitochondria, substances inside the cell nucleus.
Even though the health authorities and Merck have repeatedly denied any serious injury from Gardasil, medical doctors and research scientists have been approached by patients, triggering research to examine whether these vaccines cause harm, and if they do, to determine the cause.
Dr. Jesper Mehlsen, a medical doctor in Denmark with more than 35 years of experience in autonomic nervous system disorders, diagnosed Marika with an autoimmune reaction likely triggered by the HPV vaccine, meaning Marika’s immune system attacked her own nerves, as previously reported in Part 2 of this series.
Not only Marika but also Paula and Sara (from Part 2) may also have experienced autoimmune-induced severe injuries. Some of these girls can no longer walk or even stand, and they’ve all lost their ability to lead normal lives.
Biologist Gerd Wallukat, an HPV vaccine-related autoantibodies testing expert, stated in the “Under the Skin” documentary, “For many diseases, the doctors have not yet realized that this could be an autoimmune disorder.”
Mr. Wallukat has established a special method to detect suspicious antibodies using heart cells to beat at a specific frequency. This beat rate is measured and used as a basis for determining the presence of antibodies in the blood. An increase in the beat rate means that antibodies are present, indicating an autoimmune disorder.
The immune attack on our cells’ energy factory (mitochondria) clearly explains the severe fatigue experienced by Sesilje and Elizabeth. Both have tested positive for three types of autoantibodies.
Merck ‘Upgraded’ Aluminum Toxicity
According to Mr. Exley, “We can buy all of the usual aluminum adjuvant used in clinical vaccines, but we cannot get hold of that particular one that’s used in Gardasil. No one will share that with us.” (“Under the Skin” documentary)
What makes Merck’s Gardasil so unique? AAHS was patented by Merck in 2012. However, there may be other trade secrets not disclosed in the patent.
To stimulate an enhanced immune response intended to last for 50 years, Merck added the particularly toxic aluminum-based novel adjuvant, AAHS, as a proprietary form of aluminum to the Gardasil vaccine.
Compared with traditional aluminum, AAHS has a smaller particle size, faster dissolution time, higher uptake by immune cells, and absorbs more antigens, resulting a greater toxicity to our immune system.
Moreover, the smaller the size, the faster the immune cells can swallow them. Subsequently, the faster the immune cells die, the more toxicity the vaccine will generate.
Mr. Exley commented on the chemical rationale of using AAHS: “What it appears to be, is a form of aluminum hydroxy-phosphate, in which some of the phosphate groups have been replaced by sulfate groups. We don’t know why and won’t guess why that might be a more effective adjuvant in this case than another. The sulfate group is a more acidic group than the phosphate group.” (‘Under the Skin’ documentary)
AAHS can absorb more antigens compared to traditional aluminum-based adjuvants, and AAHS is more potent in generating antibodies than old aluminum microparticles.
Furthermore, Gardasil 9 had 27 percent more serious harm, according to a systematic review, than the original version Merck rolled out in 2006.
The authors speculated it could be because Gardasil 9 contains 2.7 times more HPV proteins than the original and over two times the amount of aluminum-containing adjuvant. A 0.5 ml dose of Gardasil 9 compared to Gardasil contains 270 μg versus 100 μg virus-like particles, respectively, and 500 μg versus 225 μg of an aluminum-containing adjuvant, respectively.
Prior to publication, we invited EMA to comment on our paper and they responded with a safety assessment report on aluminum. The report states, “In conclusion, the calculations above indicate a theoretical safety concern for the 6-weekly maintenance allergen immunotherapy in children (20 kg) treated with allergen products that contain high Al amounts (> 0.5 mg) per dose.”
Obviously, the concentration of AAHS in HPV vaccines is considered high according to this limit, indicating there is already a safety concern.
A Silent Killer With Inadequate Regulation
To summarize, the clinical and experimental evidence collected so far identifies three main risks associated with vaccine aluminum:
- It can persist in the body and can’t be excreted due to binding to vaccine proteins.
- It can trigger pathological immune responses.
- It can pass through the blood-brain barrier into the central nervous system where it can trigger immuno-inflammatory processes, resulting in brain inflammation and long-term neural dysfunction.
The vast majority of people are consuming higher amounts of aluminum through dietary and non-oral intake than what expert authorities consider safe.
Based on the above risks, aluminum is a commonly used adjuvant in many vaccines including DTaP, HepB, HepA, HiB, and HPV.
Since aluminum pervades our environment, the scientific community has raised concerns regarding our exposure to aluminum for many years.
Aluminum compounds have been shown to persist for up to eight years postvaccination in the human body, and vaccine aluminum-associated symptoms may persist for up to eight years. This fact, combined with repeated environmental exposure, may account for hyperactivation of the immune system and subsequent chronic conditions such as allergies, eczema, and asthma suffered by nearly half of American children.
It’s essential to consider adherence to the principle “first do no harm” when injecting such an obvious toxin used in Gardasil into healthy people worldwide. Ethical pharmaceutical industry standards demand strict regulation.
According to Mr. Exley, “When something works and works as well as an aluminum salt does, first of all then, that’s great news. It works incredibly well, you’re doing what you want it to do. You’ve then got, well how much does it cost? Well, relatively nothing. So aluminum costs nothing in a vaccine. So that’s good—it is not adding to the price and the cost. You then say, ‘What are the regulations about the use of aluminum in everyday life?’ And you find there are none. So this is not regulated.” (“Under the Skin” documentary)
EMA’s Approval of Gardasil Aluminum Suspect
It appears that the approval of AAHS by EMA did not follow standard regulatory procedures but was arbitrary and without any documented safety data.
In order to clarify the regulatory approval process of AAHS by EMA, Dr. Christian Gluud from the UK sent emails to “AskEMA” asking the following question: “When and in what vaccine was the AAHS adjuvant first introduced?”
R. Gonzalez in the Stakeholders and Communication division of EMA responded, “To our knowledge ‘amorphous aluminum hydroxyphosphate sulfate’ was first used and licensed in Europe through the centralized procedure for Procomvax (Hib-HBV; EU MA 1999). This vaccine is no longer available in the EU (the marketing authorization expired in 2009).”
According to the EMA, AAHS was introduced in Europe in 2004, when the name of the adjuvant in the vaccine Procomvax was modified from aluminum hydroxide to AAHS. The change was requested by Merck to align the nomenclature of the adjuvant in all relevant authorized Merck vaccines at that time. The EMA explained that the adjuvant AAHS is the same chemical compound as the one initially called aluminum hydroxide, but actually, anyone with primary school knowledge would know that they are NOT the same compounds. Surprisingly, this kind of change was accepted by EMA without being questioned.
Documentation obtained by the Danish Medicines Agency shows discrepancies in the trial documents of two prelicensure clinical trials with Gardasil in 2002 and 2003. For both trials, the Agency seems to have authorized potassium aluminum sulfate as the adjuvant but not AAHS, according to the analysis.
In April 2002, Merck submitted documents to EMA regarding the production of Gardasil in the Future II trial. The documents referred to the adjuvant as AAHS in some places, whereas in other parts it described the adjuvant as potassium aluminum sulfate, highlighting a discrepancy in the adjuvant description.
In summary, the EMA reports that AAHS was introduced without any prelicensure safety evaluation. The adjuvant is described by the company to be both physically and functionally distinct from all other previously used aluminum adjuvants.
So let’s recap. Neither the old nor the new aluminum compounds in vaccines have been tested for safety using serious scientific methods. If we actually look “under the skin,” things come to light that are not mentioned in any of the package inserts. The authorities apparently do not want to question the good reputation of the vaccines and prefer to completely avoid this sensitive issue.
Whether people choose to ignore or try to hide them, the severe injuries linked to HPV vaccines are undeniable, and the toxicity of the aluminum ingredients in the HPV vaccines is undeniable.
What Dr. Lujan revealed about the root cause of the mystery illness in sheep after a massive vaccine campaign is unfortunately the same thing happening in humans after vaccination with Gardasil. Both are related to the same toxin—aluminum.
The Epoch Times contacted the EMA, FDA, and Merck for comment. No response has been received from the FDA or Merck.
The EMA responded as follows:
“Regarding your question on Gardasil, the use of aluminium adjuvant in the clinical trials is described in the European public assessment report (EPAR), which is publicly available on EMA’s website: Gardasil, INN-Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed) (europa.eu). On page 10, it is explained that the safety of the different HPV vaccine formulations has been evaluated in a total of 16,041 subjects. Of these 11,813 received quadrivalent HPV vaccine and the remaining monovalent vaccine formulations. All studies were placebo-controlled and the total population that received placebo included 9,701 subjects (the placebo was aluminium adjuvant in all studies except study 018 (pre-/adolescent safety study) which used a non-aluminium-containing placebo).”
However, based on aluminum’s documented toxicity and health impact, aluminum could never be judged as a placebo. EMA’s response has again confirmed that almost all HPV vaccine trials used aluminum as a false “placebo” control group.
EMA insists that “the safety of the aluminium adjuvant alone or in combination with the antigen is well established. Data generated from clinical trials with aluminium-containing vaccines worldwide and the safety data gathered from the use of aluminium-containing vaccines over the past six decades have shown that their safety profile is acceptable, with only local reactions as possible side effects linked to aluminium, which normally resolve in a short timeframe. In addition, a thorough safety and toxicology assessment in non-clinical studies is performed before any vaccine can enter clinical trials. There are no scientific reasons to reconsider its use.”
The assessment report provided by EMA on aluminum’s safety does not provide adequate safety and toxicology data to validate the safe use of aluminum in vaccines. On the contrary, we have found a large body of evidence of aluminum toxicity in animals and humans, especially recorded by the aluminum “placebo” group in HPV vaccine clinical trials.